Development of Novel Measures of Cognition and Function for Alzheimer’s Disease Prevention Trials
Sponsor:
Brief Summary:
psychometrics and reduced practiced effects. They will be deployed in a parallel group study
in which participants are randomized to assessment type (novel vs established) and receive
serial assessments over a one year period in order to highlight contrasts between novel and
established measures.
Criteria
1. English speaking participants, ages 60-85 years
2. MMSE score of 24 or greater
3. Logical Memory II score of 9 or greater for subjects with 16 or more years of
education, 5 or more for subjects with 8-15 years of education, and 3 or greater for
subjects with 0-7 years of education
4. Presence of subjective memory complaints not exclusionary
5. A family member or other individual who is in contact with the subject and consents to
serve as informant during the study.
Exclusion Criteria:
1. Diagnosis of stroke or excessive risk of CVD
2. Neurologic disease including movement disorders, MS, epilepsy, and TBI (with greater
than 15 min loss of consciousness)
3. Untreated diabetes
4. Current DSM-5 Axis I psychiatric diagnosis of schizophrenia schizoaffective disorder
or bipolar disorder; current major depression as determined by a Geriatric Depression
Scale score of greater than 5. Current alcohol or substance use disorder
5. Active treatment of cancer
6. MMSE score below 24 and Logical Memory below 9 for subjects with 16 or more years of
education, 5 for subjects with 8-15 years of education, and 3 for subjects with 0-7
years of education
7. Females who are pre-menopausal and are pregnant.
8. Use of antidepressants with large anticholinergic properties will be excluded. These
include: amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine,
isocarboxazide, lithium, maprotiline, mirtazapine, nortriptyline, tranylcypromine
trimipramine, and phenelzine.
Locations
- University of Southern California, Los Angeles, California, United States, 90033
